ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,805 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselNovaremed AG
Novaremed AG Logo
Verified· 3 sources

Novaremed AG

Summary

About the company

Novaremed AG develops non-opioid pharmaceutical therapies for the treatment of chronic neuropathic pain and peripheral neuropathies. Its lead candidate, nispomeben (NRD.E1), is an orally active small molecule in clinical development and is being evaluated in an NIH-supported Phase 2b trial for painful diabetic peripheral neuropathy with FDA Fast Track designation; an earlier-stage candidate, MP-101, targets prevention of chemotherapy-induced peripheral neuropathy.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered4
Development of non-opioid pain therapies
Development of oral, non-opioid treatment options for chronic pain and neuropathic pain as an alternative to opioids.
Development of Nispomeben
Nispomeben (NRD.E1/NRD135S.E1), an orally available non-opioid small molecule, is being developed for the treatment of painful diabetic peripheral neuropathy.
Development of MP-101
MP-101, an orally active clinical candidate, is being developed to prevent chemotherapy-induced peripheral neuropathy.
Research and clinical development in peripheral neuropathy
Research and clinical development for peripheral neuropathy and neuropathic pain, including preclinical, Phase 1 and Phase 2 programmes.
Press

Media

May 9, 2025Media
Milestones achievements for life sciences startups
startupticker.ch

Knowledge

No knowledge articles yet

Once Novaremed AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Novaremed AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Novaremed AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Novaremed AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Thiersteinerallee 17
4053 Basel

At a glance

Legal form
Corporation
UID
CHE-416.510.898
Founded
2017 · 9 years
Last commercial register change
June 30, 2026
Employees
11 to 20

Similar companies

SA
SpiroChem AG
Basel
SA
Scailyte AG
Basel
ST
Synendos Therapeutics AG
Basel
TT
TargImmune Therapeutics AG
Basel